Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06218290

A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis

Chronic Kidney Disease Requiring Chronic Dialysis Clinical Trial

Official title:
A Multicenter, Multidose, Study to Assess the Tolerability and Pharmacokinetics of Oxylanthanum Carbonate at Clinically Effective Doses in Patients With Chronic Kidney Disease on Dialysis

Clinical Trial Summary

The goal of this clinical study is to test the tolerability of oxylanthanum carbonate (OLC) in patients with chronic kidney disease on hemodialysis and have hyperphosphatemia (too much phosphorus in their blood). The main question it aims to answer is whether patients taking OLC for hyperphosphatemia are able to tolerate the drug. Participants will continue with their scheduled dialysis treatments and replace their current phosphate binder drug with OLC.

Clinical Trial Description

This is a 17-week study consisting of 4 parts. In Part 1, patients are screened for eligibility. In Part 2 patients undergo approximately 3-weeks of washout from previous phosphate binder therapy. Part 3 of the study is up to 6-week titration period where patients are treated with OLC starting at a dose level of 1500 mg/day. At the end of 2 weeks, the dose will be adjusted based on serum phosphate level, up to a maximum dose of 3000 mg/day. Part 4 of the study is a 4-week Maintenance Period with patients treated for 4 weeks on the clinically effective dose of oxylanthanum carbonate (OLC) identified in the Titration Period. Patients will return to the clinic for the End-of-Study Visit on the last day of the 4-week Maintenance Period before restarting their prescribed phosphate binder therapy. The primary endpoint will be to evaluate the tolerability of OLC (as assessed by rate of discontinuations due to treatment-related adverse events) and the secondary endpoints are the evaluation of the safety of clinically effective doses of OLC and evaluate the pharmacokinetics of OLC. Once weekly, at one of the patient's scheduled dialysis appointments and at the End-of-Study Visit, the tolerability will be assessed. After the End-of-Study Visit, patients will reinitiate standard therapy. Toxicity will be assessed during the study based on the severity grade (mild, moderate, or severe) as assessed by the Investigator. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06218290
Study type Interventional
Source Unicycive Therapeutics, Inc
Contact
Status Active, not recruiting
Phase Phase 2
Start date December 15, 2023
Completion date March 31, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT05700851 - Immuno-nutrition Supplementation in Haemodialysis N/A
Recruiting NCT02616627 - Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Completed NCT01464190 - A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients Phase 3
Recruiting NCT06040281 - Smart and Fit for Kidney Transplantation N/A
Active, not recruiting NCT03535922 - Evaluation of Routinely Measured Patient-reported Outcomes in Hemodialysis Care N/A
Completed NCT04622709 - Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis Phase 2
Completed NCT04585607 - Potential Benefits of Expanded Hemodialysis in Prevention of Sarcopenia Phase 4
Completed NCT03182699 - Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients Phase 4
Completed NCT03942744 - The Effect of High-flux Hemodialysis and On-line Hemodiafiltration on Endothelial Function. N/A
Completed NCT04549597 - Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia Phase 4
Recruiting NCT04659525 - Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia Phase 4
Completed NCT04125537 - Pathways Project: Kidney Supportive Care
Recruiting NCT03347773 - Oral Nutritional Supplement Intervention Among Hemodialysis Patients With Sarcopenic Obesity N/A
Recruiting NCT04397653 - Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients Phase 4
Active, not recruiting NCT03938285 - Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Removal N/A
Completed NCT03525223 - Modulation of Tissue Sodium in Hemodialysis Patients N/A
Completed NCT01324128 - A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients Phase 3
Not yet recruiting NCT04600193 - a Randomized Controlled Trial of the Intake of Organic and Inorganic Phosphate in Peritoneal Dialysis Patients N/A
Not yet recruiting NCT06225544 - Lumasiran in Hyperoxalaemic Patients on Haemodialysis Phase 2
Recruiting NCT05209880 - Advance Care Planning in the Emergency Department N/A